Myriad Genetics (MYGN) Revenue (2009 - 2026)

Myriad Genetics has disclosed Revenue across 18 years of filings, most recently posting $200.4 million for Q1 2026.

• In Q1 2026, Revenue rose 2.3% year-over-year to $200.4 million; the TTM figure through Mar 2026 stood at $829.0 million (changed 0.28% YoY), while the FY2025 annual figure was $824.5 million, down 1.56% from the prior year.
• Revenue retreated to $200.4 million in Q1 2026, from $209.8 million in the prior quarter.
• Over the last five years, Revenue for MYGN reached as high as $213.3 million in Q3 2024 and fell as low as $156.4 million in Q3 2022.
• The 5-year median for Revenue is $196.6 million (2023), against an average of $193.8 million.
• Annual changes were most pronounced in 2022 — Revenue declined 6.52% — and 2023, when it rose 22.7%.
• A 5-year view of Revenue shows it stood at $177.8 million in 2022, then increased by 10.57% to $196.6 million in 2023, then grew by 7.12% to $210.6 million in 2024, then fell by 0.38% to $209.8 million in 2025, then retreated by 4.48% to $200.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $200.4 million, $209.8 million, and $205.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.